pioglitazone; rosiglitazone; placebo
Проводит ГлаксоСмитКляйн ЛЛС
Страница компанииAVANDIA CV Outcomes Study: Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk For Cardiovascular Disease
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00879970/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование прекращено досрочно, новых участников не набирают.
- Возраст участников: от 50 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 1332 чел. во всех странах исследования.
- Плановая дата окончания (11.2010) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 19 · невключение: 22
Критерии включения
- Men or women with: a) newly detected type 2 diabetes based on a fasting plasma glucose greater than or equal to 7.0 mmol/l (126 mg/dL) or a 2 hour plasma glucose (FPG) greater than or equal to 11.1 mmol/l (200 mg/dL) on an oral glucose tolerance test, or b) a history of type 2 diabetes
- Hemoglobin A1c (A1C) 6.5-9.5% inclusive (for assays with upper limit of normal of 6%) within one month of screening
- Age ≥ 50 years and evidence of vascular disease defined as ≥1of:
- prior myocardial infarction
- prior stroke
- coronary, carotid or peripheral artery revascularization ≥ 4 years earlier
- previous documented myocardial ischemia on either an exercise stress test or on any cardiac imaging, or previous unstable angina with ECG changes or cardiac enzyme elevation OR
- Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of:
- microalbuminuria or proteinuria
- history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram
- 50% stenosis on any imaging of coronary, carotid or lower extremity arteries
- ankle/brachial index <0.9 OR
- Age ≥ 60 years and at least 2 of the following cardiovascular disease risk factors:
- current tobacco use
- LDL-c ≥3.4 mmol/L (130 mg/dL) or on a lipid lowering medication
- HDL-c < 1.0 mmol/L (40 mg/dL) for men and < 1.3 mmol/L (50 mg/dL) for women or triglycerides ≥ 2.3 mmol/L (200 mg/dL)
- BP lowering medication use or untreated SBP ≥ 140 mmHg or DBP ≥ 95 mmHg
- Waist to hip ratio > 1.0 for men and > 0.8 for women
- On no insulin and on less than or equal to 2 anti-diabetes drugs where at least one drug is at or below the half-maximal dose (as indicated in the MOP) with stable dosing for 10 weeks prior to screening
Критерии невключения
- Type 1 diabetes
- Current need for insulin treatment
- Symptomatic hyperglycemia requiring immediate therapy in the judgment of the physician
- An acute cardiovascular event within 30 days prior to randomization
- Symptomatic heart failure (i.e. New York Heart Association class II or higher) or any episode of previous pulmonary edema or known ejection fraction < 0.4 or current use of loop diuretics
- Any fracture within the past 1 year
- Currently planned coronary, carotid or peripheral artery revascularization or cardiac valve surgery
- Coronary, carotid or peripheral artery revascularization within the 4 years prior to screening in the absence of angina, MI, or stroke in the intervening period
- End stage renal disease requiring renal replacement therapy
- Receiving drug therapy to treat liver disease
- A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer (other than prophylactic)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level > 2.5 times the upper limit of normal
- A prior heart transplant or awaiting a heart transplant
- Previous or current hypercalcemia, hyperparathyroidism, osteomalacia or other contraindication for vitamin D therapy
- Regular use of or indication for greater than 400IU of vitamin D daily
- Clinically or medically unstable with expected survival < 1 year
- Unwillingness to permit sites to contact their primary physicians to communicate information about the study and the participant's data
- Any other factor likely to limit protocol compliance or reporting of adverse events
- Inability to discontinue a TZD (if taking one) in the judgement of the physician/investigator
- Contraindications to or history of hypersensitivity to the investigational products
- History of renal stones within the past 2 years
- Participation in another clinical trial of an investigational agent
Источник: ClinicalTrials.gov, NCT00879970 · запись обновлена в реестре 18 апреля 2017.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 13
- Number of Participants With the Indicated Components of the Composite Cardiovascular Outcome for Thiazolidinedione (TZD) — From Randomization at Visit 3 up to the Final Visit (average of 162 days)
- Number of Participants With the Indicated Components of the Composite Outcome for Vitamin D — From Randomization at Visit 3 to Final Visit (up to 162 days)
Цель исследования
This study will answer two separate questions.
The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard of care without rosiglitazone or pioglitazone in patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease.
The second question will compare the effects of long-term supplementation of vitamin D on death and cancer
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00879970 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.